Skip to main content
TipRanks
Go Ultimate75% OFF

Crescent Biopharma (CBIO) Stock Statistics & Valuation Metrics

1,027 Followers

Total Valuation

Crescent Biopharma has a market cap or net worth of $550.37M. The enterprise value is $286.93M.

Market Cap
$550.37M
Enterprise Value
$286.93M

Share Statistics

Crescent Biopharma has 38,895,443 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
38,895,443
Owned by Insiders
11.26%
Owned by Institutions
29.33%

Financial Efficiency

Crescent Biopharma’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -74.58%.

Return on Equity (ROE)
-0.76
Return on Assets (ROA)
-0.64
Return on Invested Capital (ROIC)
-74.58%
Return on Capital Employed (ROCE)
-0.75
Revenue Per Employee
246.45K
Profits Per Employee
-3.50M
Employee Count
44
Asset Turnover
0.05
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Crescent Biopharma is -2.00. Crescent Biopharma’s PEG ratio is -0.01.

PE Ratio
-2.00
PS Ratio
36.69
PB Ratio
2.01
Price to FCF
-3.39
Price to Operating Cash Flow
-6.73
PEG Ratio
-0.01

Income Statement

In the last 12 months, Crescent Biopharma had revenue of 10.84M and earned -153.94M in profits. Earnings per share was -14.78.

Revenue
10.84M
Gross Profit
10.84M
Operating Income
-152.63M
Pretax Income
-151.94M
Net Income
-153.94M
EBITDA
-149.67M
Earnings Per Share (EPS)
-14.78

Cash Flow

In the last 12 months, operating cash flow was -82.08M and capital expenditures -80.35M, giving a free cash flow of -162.43M billion.

Operating Cash Flow
-82.08M
Free Cash Flow
-162.43M
Free Cash Flow per Share
-4.16

Dividends & Yields

Crescent Biopharma pays an annual dividend of $0.24, resulting in a dividend yield of ―

Dividend Per Share
$0.24
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-30.90%
Earnings Yield
-31.86%

Stock Price Statistics

Beta
1.54
52-Week Price Change
9.01%
50-Day Moving Average
14.94
200-Day Moving Average
16.07
Relative Strength Index (RSI)
52.34
Average Volume (3m)
348.19K

Important Dates

Crescent Biopharma upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 12, 2026
Next Earnings Date
Mar 04, 2027
Ex-Dividend Date
Jan 13, 2023

Financial Position

Crescent Biopharma as a current ratio of 6.56, with Debt / Equity ratio of 0.81%

Current Ratio
6.56
Quick Ratio
6.56
Debt to Market Cap
0.00
Net Debt to EBITDA
1.41
Interest Coverage Ratio
-69.85

Taxes

In the past 12 months, Crescent Biopharma has paid 2.00M in taxes.

Income Tax
2.00M
Effective Tax Rate
-0.01

Enterprise Valuation

Crescent Biopharma EV to EBITDA ratio is -1.34, with an EV/FCF ratio of -1.47.

EV to Sales
15.91
EV to EBITDA
-1.34
EV to Free Cash Flow
-1.47
EV to Operating Cash Flow
-2.91

Balance Sheet

Crescent Biopharma has $289.36M in cash and marketable securities with $2.46M in debt, giving a net cash position of $286.90M billion.

Cash & Marketable Securities
$289.36M
Total Debt
$2.46M
Net Cash
$286.90M
Net Cash Per Share
$7.38
Tangible Book Value Per Share
$7.02

Margins

Gross margin is 99.55%, with operating margin of -1216.61%, and net profit margin of -1173.97%.

Gross Margin
99.55%
Operating Margin
-1216.61%
Pretax Margin
-1174.95%
Net Profit Margin
-1173.97%
EBITDA Margin
-1187.82%
EBIT Margin
-1189.49%

Analyst Forecast

The average price target for Crescent Biopharma is $31.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$31.00
Price Target Upside
119.08% Upside
Analyst Consensus
Strong Buy
Analyst Count
5
Revenue Growth Forecast
―
EPS Growth Forecast
67.56%

Scores

Smart Score
7
AI Score
50